The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}

European Urology, Supplements

Volumn 6, Issue 3, 2007, Pages 327-333

  Miller, Kurt ^a   Abrahamsson, Per Anders ^b   Akakura, Koichiro ^c   Debruyne, Frans M J ^d   Evans, Christopher P ^e   Klotz, Laurence ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Prostate cancer; PSA; PSA doubling time; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; KINETICS; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

EID: 33846408703     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.12.001     Document Type: Review

References (42)

1. Partin A.W., Carter H.B., Chan D.W., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143 (1990) 747-752
2. Nadler R.B., Humphrey P.A., Smith D.S., Catalona W.J., and Ratliff T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154 (1995) 407-413
3. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
4. Yan Y. Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma. Cancer 92 (2001) 776-780
5. Raaijmakers R., Wildhagen M.F., Ito K., et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63 (2004) 316-320
6. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
7. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
8. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection V.I.2006. Available at www.nccn.org. Accessed 22 November 2006.
9. Catalona W.J., and Loeb S. Making prostate-specific antigen testing more effective. Urol Oncol 24 (2006) 177-179
10. Aus G, Abbou CC, Bolla M, et al. European Association of Urology Guidelines on Prostate Cancer. Available at http://wwwurowebnl/files/uploaded_files/2005Prostate%20Cancer.pdf. Accessed 19 December 2005.
11. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
12. Catalona W.J., and Loeb S. The PSA era is not over for prostate cancer. Eur Urol 48 (2005) 541-545
13. Catalona W.J. Serum PSA correlates more strongly with the percentage of prostate cancer and cancer volume than with prostate size. J Urol 173 (2005) 257 (abstract no. 949)
14. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399
15. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
16. Fang J., Metter E.J., Landis P., and Carter H.B. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59 (2002) 889-893
17. Berger A.P., Dieble M., and Steiner H. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. J Urol 173 (2005) 402
18. Schröder F.H., Roobol M.J., van der Kwast T.H., Kranse R., and Bangma C.H. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
19. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol 49 (2006) 418-419
20. Catalona W.J., Richie J.P., deKernion J.B., et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152 (1994) 2031-2036
21. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
22. Becker C., Piironen T., Pettersson K., et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163 (2000) 311-316
23. Haese A., Graefen M., Steuber T., et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 170 (2003) 2269-2273
24. Mikolajczyk S.D., and Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 (2003) 86-91
25. Becker C., Piironen T., Pettersson K., Hugosson J., and Lilja H. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol 170 (2003) 1169-1174
26. Aslan G., Irer B., Kefi A., Celebi I., Yorukoglu K., and Esen A. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. Int Urol Nephrol 37 (2005) 511-514
27. Vaisanen V., Pettersson K., Alanen K., Viitanen T., and Nurmi M. Free and total human glandular kallikrein 2 in patients with prostate cancer. Urology 68 (2006) 219-225
28. Stephan C., Jung K., Nakamura T., Yousef G.M., Kristiansen G., and Diamandis E.P. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 13 (2006) 238-243
29. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245-2249
30. Shariat S.F., Abdel-Aziz K.F., Roehrborn C.G., and Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Eur Urol 49 (2006) 293-302
31. Carter H.B., Ferrucci L., and Metter E.J. PSA velocity and risk of prostate cancer death in the Baltimore Longitudinal Study of Aging. J Urol 173 (2005) 257 (abstract no. 951)
32. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
33. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
34. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 47 (2005) 16-21
35. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
36. Sengupta S., Myers R.P., Slezak J.M., Bergstralh E.J., Zincke H., and Blute M.L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
37. Gillatt D., Keane T., Miller K., and Preface. Eur Urol Suppl 6 (2007) 325-326
38. Brett J., Watson E., Hewitson P., et al. PSA testing for prostate cancer: an online survey of the views and reported practice of general practitioners in the UK. BMC Fam Pract 6 (2005) 24
39. Grubb R.L., Roehl K.A., Antenor J.A., and Catalona W.J. Results of compliance with prostate cancer screening guidelines. J Urol 174 (2005) 668-672
40. Moul J.W. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer 2 (2003) 87-97
41. Whittemore A.S., Cirillo P.M., Feldman D., and Cohn B.A. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans. J Urol 174 (2005) 872-876
42. Yanke B.V., Gonen M., Scardino P.T., and Kattan M.W. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 173 (2005) 421-424